Adoptive cell transfer (ACT) is a burgeoning therapeutic modality within human immuno-oncology. Novel approaches towards ACT are being developed in the pre-clinical setting faster than they can be evaluated in human clinical trials. Many of the therapeutic approaches used in human medicine have already been evaluated to some degree in canine patients. While this form of immunotherapy in veterinary medicine is still in its infancy, as these approaches develop, canine ACT will become a tool for both the veterinary oncologist and the translational researcher. This review details canine ACT trials to date, with attention given to the precedents provided by human oncology.

中文翻译：

---

来来回回：将过继细胞疗法转化为犬类癌症并改善人类治疗

过继细胞转移 (ACT) 是人类免疫肿瘤学中一种新兴的治疗方式。新的 ACT 方法在临床前环境中的开发速度快于它们在人体临床试验中的评估速度。许多用于人类医学的治疗方法已经在犬类患者中进行了一定程度的评估。虽然兽医学中这种形式的免疫疗法仍处于起步阶段，但随着这些方法的发展，犬 ACT 将成为兽医肿瘤学家和转化研究人员的工具。本综述详细介绍了迄今为止的犬类 ACT 试验，并关注人类肿瘤学提供的先例。